Addison's Disease Self Help Group

 TOPICS INDEX ADDISON'S INFO   COMMUNICATION  LIVING WELL FORUM MEMBERS SITE INFO

ADSHG Topics provide you with informed and up to date news and information about living with Addison's.

addisons.org.uk Thursday, 04. June 2009 23:07:26

 HOME  TOPICS INDEX   TOPICS
Gilmore review of prescription charges, April 2009

By:  Katherine White   Sunday, 31 May 2009

In its submission to the Gilmore review of prescription charges, the ADSHG recommended that prescription charges could be phased out in a cost-neutral way by placing patients with long-term medication dependencies on three-six month repeat prescriptions, as appropriate. This could generate savings on pharmacy dispensing fees and associated costs estimated at potentially £450 million per annum.

 

Read: Letter to Professor Ian Gilmore

Re: Reforming prescription charges (letter 6 April 2009)

PDF icon 293 kbytes
       
 

Summary of main points

1. Prescription charges and length of repeat prescriptions for patients with long-term medication dependencies are two issues that must be reformed in tandem, because of inevitable concerns over the potential for increased medicines wastage where medication is a “free good” and because restricting patients to just 28-days’ supply at a time unnecessarily and artificially limits the medical benefit.

2. The current main mechanism for wastage prevention, 28-day rationing, is inefficient when applied to drugs with a stable, long-term dependency. It is costing the NHS hundreds of millions of pounds in additional expenditure in pharmacy costs.

3. Our estimates suggest it would be possible to phase out prescription charges for the entire UK population on a cost-neutral basis, through a one-third reduction of the current spending on pharmacy dispensing fees and associated charges. The prescription charge brings in around £450 million pounds in revenue, which is about one-third of the £1.36 billion spent on pharmacy costs. A cost-neutral phasing out of the prescription charge could be achieved by extending the length of repeat prescriptions for patients with a stable, long-term medication dependency from the current 28 days to between three and six months, as appropriate.

       
Read: Background information for the Gilmore review

Monitoring the impact of 28-day repeat prescribing: do the benefits outweigh the costs?

PDF icon 197 kbytes
Read: Supplementary information to the Gilmore review on prescription charges.

Medicines wastage: how big is the problem?

 

PDF icon 214 kbytes

 

 
   
 RELATED TOPICS  
  Media and Commentary
  Addison’s Clinical Advisory Panel
  What is Addison's disease?
  Publications and news releases
 
RELATED LINKS
 
 

 
© Copyright 2009 Addison's Disease Self Help Group (ADSHG), registered charity no: 1106791 - All rights reserved.
 Editorial Team: Deana Kenward, Katherine White - Technical Design: Nick Willson
About us  Legal & Privacy Information    ADSHG Website Alert Sitemap Search Help